Xavier Ramnik 4

What Happened

• Xavier Ramnik, a director of MoonLake Immunotherapeutics (MLTX), was granted a derivative award on 2026-06-17 giving him the right to purchase 22,195 Class A Ordinary Shares. The reported acquisition price is $0.00 (grant of an option/award), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-18 (timely).
• Transaction type/code: Grant / Award (A) of a derivative security; amount: 22,195 shares; price shown: $0.00.
• Vesting: The option vests in full on the earlier of (i) June 17, 2027 or (ii) the issuer’s next annual general meeting, subject to continued service (see footnote F1).
• Shares owned after transaction: Not specified on the provided Form 4 excerpt.
• Filing timeliness: Reported the next day; no late-filing indication in this record.

Context

• This is a grant of a right to purchase shares (an option or similar derivative), not an exercise or open-market purchase/sale. It’s a compensation award that will only convert into purchasable shares if/when vested and exercised according to plan terms.
• Such grants are common for directors as part of compensation and do not, by themselves, indicate buying or selling sentiment. If the options are later exercised or the underlying shares are sold, separate Form 4s would report those transactions.